Shanghai Medicilon Inc.: what insiders have been doing
Shanghai Medicilon Inc. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). In the past year (6 November 2025 to 6 November 2026), 1 filing came from 1 insider.
There is no open-market purchase to report; the filings show 1 sale worth €70k by 1 insider. 李志刚 filed the largest sale, €70k, on 14 August 2026.
Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 1 filing in twelve months, the company is quieter than the median of 2 filings across the 514 companies we follow on the same exchange. The full history, which starts in 2021, counts no purchases against 5 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,200 shares@ CN¥811.2198100.0% of flowA股XSHGSSE:273000001276536670
- 124,000 shares100.0% of flowA股XSHGSSE:173000006622754180
- 5,000 shares100.0% of flowA股XSHGSSE:173000006512050400
- 3,000 shares100.0% of flowA股XSHGSSE:173000005713932350
- 1,700 shares100.0% of flowA股XSHGSSE:173000005176769500
5 of 5 declarations
About Shanghai Medicilon Inc.
美迪西 is a company specializing in the healthcare and pharmaceutical sector, listed on the XSHG market. It focuses on developing innovative solutions for the pharmaceutical industry.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
